Moleculin Biotech reports Q3 results
- Moleculin Biotech press release (MBRX): Q3 Diluted loss per share of $9.59 vs. $340.43 Y/Y.
- Cash and cash equivalents totaled $7.3M as of September 30, 2026, compared with $8.9M as of December 31, 2025.
Net loss of $6.5M vs. $25.4M Y/Y, down 74% Y/Y, primarily reflecting the absence of a $20.6M non-cash loss on issuance of warrant liabilities in the prior-year period.
R&D expenses of $4.5M, up 20% Y/Y.
More on Moleculin Biotech
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.